"Advances in Hepatology" ed. by Luis Rodrigo, Ian James Martins, Xiaozhong Guo, Xingshun Qi

This book discusses clinical advances in hepatology, with a focus on metabolic diseases and chronic hepatitis C.

The development of direct-acting antiviral (DAA) agents for the treatment of hepatitis C virus (HCV) infection in 2010 has completely transformed the management of this disease. This transformative nature of DAA therapy underpins the goal of the World Health Organization (WHO) to eliminate HCV infection as a public health threat by 2030. The advantages of using these therapies include high efficacy (sustained virological response rate >95%) with minimal side effects, good tolerability, easy drug administration (once-daily oral dosing) and short duration of treatment (8-12 weeks). The commercialization of second-generation DAA agents due to their high effectiveness, few side-effects and pangenotypic action. This transformative nature of DAA therapy underpins the goal of the WHO to eliminate HCV infection as a public health threat by 2030.

Contents
1. Discovery of Hepatitis C Virus: Nobel Prize in Physiology and Medicine 2020
2. Hepatitis C: An Overview
3. Extrahepatic Manifestations of Hepatitis C Infection
4. Host-Targeting Antivirals for Treatment of Hepatitis C
5. The Influence of Protease Inhibitors on the Evolution of Hepatitis C in Patients with HIV and HCV Co-Infection
6. Liver Transplantation and HCV Genotype 4
7. Hepatocellular Carcinoma and Antiviral Therapies in HCV Chronic Infection
8. Diagnosis of Nonalcoholic Steatohepatitis
9. Treatment of Nonalcoholic Fatty Liver Disease through Changes in Gut Microbiome and Intestinal Epithelial Barrier
10. The Role of Bariatric Surgery in Fatty Liver
11. Spontaneous Bacterial Peritonitis: Physiopathological Mechanism and Clinical Manifestations
12. Hepatorenal Syndrome
13. Treatment Approach in Patients with Decompensated Liver Cirrhosis
14. Therapy that Targets Growth Factor Receptors: Novel Approach for Liver Cirrhosis Treatment


More : You find here